| Pharmaceutical Information |
| Drug Name |
Flutemetamol f-18 |
| Drug ID |
BADD_D00944 |
| Description |
Flutemetamol (18F) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18. It is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. |
| Indications and Usage |
Flutemetamol F18 is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB09151
|
| KEGG ID |
D10231
|
| MeSH ID |
C581552
|
| PubChem ID |
15950376
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
17156-067 |
| UNII |
L49M066S0O
|
| Synonyms |
flutemetamol | (18F)flutemetamol | flutemetamol F-18 | Vizamyl |
|
| Chemical Information |
| Molecular Formula |
C14H11FN2OS |
| CAS Registry Number |
765922-62-1 |
| SMILES |
CNC1=C(C=C(C=C1)C2=NC3=C(S2)C=C(C=C3)O)F |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
